Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX), a late-clinical stage biotechnology company, will announce its Q1 2024 financial and operational results on May 22, 2024, before US and EU markets open.
The announcement will be followed by a conference call and webcast at 8:00 am EDT / 2:00 pm CEST, featuring CEO Laurent Levy and CFO Bart van Rhijn, who will review the results and provide a business update.
The company's next Annual General Meeting (AGM) is scheduled for May 28, 2024, at its Paris headquarters. Meeting details and related documents are available on NANOBIOTIX's website.
NANOBIOTIX has announced that the US FDA has issued a Study May Proceed Letter for a new Phase 2 study evaluating NBTXR3 in patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The study is sponsored by Johnson & Johnson Enterprise Innovation Inc., a subsidiary of Johnson & Johnson. This progress is part of Nanobiotix's global licensing agreement with Janssen Pharmaceutica NV, aimed at expanding the application of NBTXR3 to new cancer indications. The acceptance of this protocol by the FDA is seen as a significant step towards potentially providing improved treatment outcomes for a new group of cancer patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.